---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-24-000110"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:17:05.890898+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Recursion announces Roche exercises option for first Neuroscience Phenomap; receives $30M fee

## Summary
- Roche exercised option for first Neuroscience Phenomap under 2021 Collaboration Agreement.
- Recursion to receive $30 million Acceptance Fee from Roche.
- Option exercised by Genentech, a member of the Roche Group.

## SEC filing metadata
- accession: 0001601830-24-000110
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000110/0001601830-24-000110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000110/rxrx-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-24-000110
- JSON: https://secwatch.observer/filing/0001601830-24-000110.json
- Plain text: https://secwatch.observer/filing/0001601830-24-000110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.